TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9200
-0.0400 (-2.04%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.9600
Open1.9900
Bid1.73 x 2200
Ask1.98 x 1000
Day's Range1.9100 - 1.9900
52 Week Range0.3600 - 9.6000
Volume129,067
Avg. Volume857,959
Market Cap4.591M
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-28.52
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Tonix Pharmaceuticals Announces New Board Member, James Treco

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Directors, effective immediately. Mr. Treco assumes the seat held by Charles Mather, who has stepped down from the position of company director that he has held since 2011. Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, “We are pleased to welcome Mr. Treco to the Tonix Board.

  • How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?
    Simply Wall St.17 days ago

    How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...

  • GlobeNewswire19 days ago

    Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on February 11, 2019. A live webcast and subsequent archived recording of the Company presentations will be available under the IR Events tab of the Investor Relations section of the Tonix Pharmaceuticals website at www.tonixpharma.com.

  • Zacks Small Cap Research2 months ago

    TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…

    2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later. 3) The study will include both civilian and military PTSD patients, while the HONOR trial had limited inclusion to only those with military-related PTSD.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On November 28, 2018, Tonix effected a 1-for-10 reverse stock split of its outstanding common stock intended to increase the per share trading price of Tonix’s common stock to satisfy the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1) (the “Bid Price Rule”).

  • Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
    InvestorPlace3 months ago

    Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today

    Tonix Pharmaceuticals (NASDAQ:TNXP) says that it is holding a new public offering that has a total value of $15 billion. The company notes that it plans to use funds from this public offering to fuel a new Phase 3 study for TNX-102 SL, which is its lead product candidate. According to Tonix Pharmaceuticals, it will be selling Class A and Class B shares of its stock during the public offering.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Prices $15,000,000 Public Offering

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today the pricing of an underwritten public offering with expected total gross proceeds of $15,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL, and for working capital and other general corporate purposes. The securities offered by the Company consist of (i) Class A Units each consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock at a price of $3.50 per Class A Unit, and (ii) Class B Units each consisting of one share of Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into 286 shares of Common Stock per share of Series A Preferred Stock, and Warrants to purchase 286 shares of Common Stock, at a combined price of $1,000 per Class B Unit.

  • ACCESSWIRE3 months ago

    Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD. New composition of matter patent was issued in November which expands the Company's intellectual property protection for Tonmya, or TNX-102 SL, in the U.S. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer's disease and fibromyalgia.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). The minutes are consistent with the preliminary guidance the Company received at the meeting and confirm FDA’s acceptance of the new Phase 3 “RECOVERY” study design. As previously communicated, the Company plans to start the RECOVERY trial for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019.

  • Zacks Small Cap Research3 months ago

    TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…

    On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the company will be initiating a new Phase 3 trial for TNX-102 SL in posttraumatic stress disorder (PTSD) in the first quarter of 2019. 1) The primary endpoint will be the change from baseline in CAPS-5 score at 4 weeks. 2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR study included individuals who experienced a trauma from 2001 or later.

  • Associated Press3 months ago

    Tonix: 3Q Earnings Snapshot

    The New York-based company said it had a loss of 57 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Shares of Tonix Pharmaceuticals were flying higher in Wednesday’s session on news that the company plans to start a new Phase 3 trial of Tonmya, a drug formulation ...

  • ACCESSWIRE4 months ago

    Healthcare Market Growth Could Fuel These Stocks

    CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / The bounce back for healthcare stocks started in May 2018 but faced some selling pressure in more recent trading session as market volatility grew. As far as healthcare stocks are concerned, 2018 and most likely 2019 could be ready to see a jump in deals. According to a report* from McKinsey & Company, the number of healthcare services deals among institutional investors nearly doubled from 2012 to 2017.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.